Brokerage Firm Rating Update on Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (INO) : 5 analysts are covering Inovio Pharmaceuticals (INO) and their average rating on the stock is 1.4, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Inovio Pharmaceuticals (INO) : The most positive equity analysts on Inovio Pharmaceuticals (INO) expects the shares to touch $31, whereas, the least positive believes that the stock will trade at $13 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $19.75 with an expected fluctuation of $7.8 from the mean.


For the current week, the company shares have a recommendation consensus of Buy. Also, Maxim Group downgrades its view on Inovio Pharmaceuticals (NASDAQ:INO) according to the research report released by the firm to its investors. The shares have now been rated Hold by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on August 9, 2016.

Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $8.88 and touched an intraday high of $9.09 on Wednesday. During the day, the stock corrected to an intraday low of $8.87, however, the bulls stepped in and pushed the price higher to close in the green at $9.05 with a gain of 0.56% for the day. The total traded volume for the day was 632,202. The stock had closed at $9 in the previous trading session.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.